NTRK1 and cancer: In 2018, the FDA approved an inhibitor of Trk receptors, larotrectinib (Vitrakvi) for therapy of tumors with NTRK gene fusions.212,213 While in 2019 was approved entrectinib (Rozlytrek), a potent ATP-competitive inhibitor for Trks.205,214 It is necessary to continue the research on the role of neurotrophins in cancer and the effects of Trk inhibitors in conjunction with conventional therapy.